First‐line R‐CVP versus R‐CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4

R‐CVP (cyclophosphamide, vincristine, prednisone) and R‐CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone + rituximab) are immunochemotherapy regimens frequently used for remission induction of indolent non‐Hodgkin lymphomas (iNHLs). Rituximab maintenance (RM) significantly improves progr...

Descripción completa

Detalles Bibliográficos
Autores principales: Walewski, Jan, Paszkiewicz‐Kozik, Ewa, Michalski, Wojciech, Rymkiewicz, Grzegorz, Szpila, Tomasz, Butrym, Aleksandra, Giza, Agnieszka, Zaucha, Jan M., Kalinka‐Warzocha, Ewa, Wieczorkiewicz, Agata, Zimowska‐Curyło, Dagmara, Knopińska‐Posłuszny, Wanda, Tyczyńska, Agata, Romejko‐Jarosińska, Joanna, Dąbrowska‐Iwanicka, Anna, Gruszecka, Beata, Jamrozek‐Jedlińska, Maria, Borawska, Anna, Hołda, Waldemar, Porowska, Agnieszka, Romanowicz, Agnieszka, Hellmann, Andrzej, Stella‐Hołowiecka, Beata, Deptała, Andrzej, Jurczak, Wojciech
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Haematological Malignancy – Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154735/
https://www.ncbi.nlm.nih.gov/pubmed/31792945
http://dx.doi.org/10.1111/bjh.16264

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154735/
https://www.ncbi.nlm.nih.gov/pubmed/31792945
http://dx.doi.org/10.1111/bjh.16264

Ejemplares similares